[177Lu]Lu-AKIR001 First-in-human Study

The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of \[177Lu\]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in patients with irresectable or metastatic CD44v6-expressing solid malignancies for whom no reasonable systemic treatment options are be available. The main question it aims to answer is: • What is the toxicity profile of the study drug \[177Lu\]Lu-AKIR001 according to the rate of Dose Limiting Toxicities and (Severe) Adverse Events? Participants will receive one \[177Lu\]Lu

Trial Details

NCT ID
NCT06639191
Phase
EARLY_PHASE1
Sponsor
Karolinska University Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • [177Lu]Lu-AKIR001
Locations (sample)
  • Stockholm, Stockholm County, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Participant must be 18 years of age or older
  • Willing and able to provide written informed consent
  • Participant has one of the following histologically confirmed metastatic or locally advanced irresectable CD44v6 expressing (confirmed in pre-scree…
  • For anaplastic, poorly differentiated and radioiodine refractory differentiated thyroid cancer (ATC, PDTC, RAI-R DTC):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →